The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism
Open accessAbstract
Rationale: Histone deacetylase (HDAC) inhibitors are efficacious in models of hypertension-induced left ventricular heart failure. The consequences of HDAC inhibition in the context of pulmonary hypertension with associated right ventricular cardiac remodeling are poorly understood. Objective: This study was performed to assess the utility of selective small-molecule inhibitors of class I HDACs in a preclinical model of pulmonary hypertension. Methods and Results: Rats were exposed to hypobaric hypoxia for 3 weeks in the absence or presence of a benzamide HDAC inhibitor, MGCD0103, which selectively inhibits class I HDACs 1, 2, and 3. The compound reduced pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. MGCD0103 improved pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. Similar results were obtained with an independent class I HDAC-selective inhibitor, MS-275. Reduced pulmonary arterial pressure in MGCD0103-treated animals was associated with blunted pulmonary arterial wall thickening because of suppression of smooth muscle cell proliferation. Right ventricular function was maintained in MGCD0103-treated animals. Although the class I HDAC inhibitor only modestly reduced right ventricular hypertrophy, it had multiple beneficial effects on the right ventricle, which included suppression of pathological gene expression, inhibition of proapoptotic caspase activity, and repression of proinflammatory protein expression. Conclusions: By targeting distinct pathogenic mechanisms, isoform-selective HDAC inhibitors have potential as novel therapeutics for pulmonary hypertension that will complement vasodilator standards of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brunet, A., Park, J., Tran, H., Hu, L. S., Hemmings, B. A., & Greenberg, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.952-965.2001 · Cited by 860
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Therapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
Self-citation
Cited by
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan, T., Ormiston, M. L., Ryan, J. J., & Archer, S. L. (2018) · BMJ · doi:10.1136/bmj.j5492 · Cited by 998
Genetics and Genomics of Pulmonary Arterial Hypertension
Soubrier, F., Chung, W. K., Machado, R., Grünig, E., Aldred, M., Geraci, M., Loyd, J. E., Elliott, C. G., Trembath, R. C., Newman, J. H., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.035 · Cited by 616
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Tuder, R. M., Archer, S. L., Dorfmüller, P., Erzurum, S. C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K. R., & Morrell, N. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.025 · Cited by 585
Self-citationThe Adventitia: Essential Regulator of Vascular Wall Structure and Function
Stenmark, K. R., Yeager, M. E., El Kasmi, K. C., Nozik-Grayck, E., Gerasimovskaya, E. V., Li, M., Riddle, S. R., & Frid, M. G. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183802 · Cited by 464
Self-citationHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
Metadata
- Authors
- Cavasin, M. A., Demos-Davies, K., Horn, T. R., Walker, L. A., Lemon, D. D., Birdsey, N., Weiser-Evans, M. C. M., Harral, J., Irwin, D. C., Anwar, A., Yeager, M. E., Li, M., Watson, P. A., Nemenoff, R. A., Buttrick, P. M., Stenmark, K. R., & McKinsey, T. A.
- Venue
- Circulation Research
- Published
- 2012-03-02
- Volume
- 110
- Issue
- 5
- Pages
- 739-748
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2157391786
- Cited by
- 175
- References
- 3
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism. https://app.cochat.ai/papers/10.1161/circresaha.111.258426
- The paper
- Cavasin, M. A., Demos-Davies, K., Horn, T. R., Walker, L. A., Lemon, D. D., Birdsey, N., Weiser-Evans, M. C. M., Harral, J., Irwin, D. C., Anwar, A., Yeager, M. E., Li, M., Watson, P. A., Nemenoff, R. A., Buttrick, P. M., Stenmark, K. R., & McKinsey, T. A. (2012). Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism. Circulation Research. https://doi.org/10.1161/circresaha.111.258426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.